{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:50:06Z","timestamp":1790394606689,"version":"4.1.0"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNCI J Natl Cancer Inst"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1093\/jnci\/djw263","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T19:07:07Z","timestamp":1476299227000},"page":"djw263","source":"Crossref","is-referenced-by-count":9,"title":["Recommendations for Clinical Trial Development in Mantle Cell Lymphoma"],"prefix":"10.1093","volume":"109","author":[{"given":"Stephen E.","family":"Spurgeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre H.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Baizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,31]]},"reference":[{"key":"2016123117301575000_109.1.djw263.1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"issue":"5","key":"2016123117301575000_109.1.djw263.2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"2016123117301575000_109.1.djw263.3","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656628"},{"key":"2016123117301575000_109.1.djw263.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"2016123117301575000_109.1.djw263.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.001"},{"key":"2016123117301575000_109.1.djw263.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"2016123117301575000_109.1.djw263.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"2016123117301575000_109.1.djw263.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2011.03.010"},{"key":"2016123117301575000_109.1.djw263.9","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.815353"},{"key":"2016123117301575000_109.1.djw263.10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.055715"},{"key":"2016123117301575000_109.1.djw263.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"issue":"8","key":"2016123117301575000_109.1.djw263.12","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood."},{"key":"2016123117301575000_109.1.djw263.13","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0036-x"},{"key":"2016123117301575000_109.1.djw263.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"issue":"9","key":"2016123117301575000_109.1.djw263.15","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin\u2019s lymphomas, version 4.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2016123117301575000_109.1.djw263.16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2015","journal-title":"Br J Haematol."},{"key":"2016123117301575000_109.1.djw263.17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"2016123117301575000_109.1.djw263.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"issue":"23","key":"2016123117301575000_109.1.djw263.19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V126.23.518.518","article-title":"Pre-transplant R-bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"2016123117301575000_109.1.djw263.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"2016123117301575000_109.1.djw263.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"2016123117301575000_109.1.djw263.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"issue":"21","key":"2016123117301575000_109.1.djw263.23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/blood.V120.21.151.151","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)","volume":"120","author":"Hermine","year":"2012","journal-title":"Blood"},{"key":"2016123117301575000_109.1.djw263.24","doi-asserted-by":"crossref","unstructured":"Le Gouill S Thieblemont C Oberic L , . Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: First interim analysis of the phase III prospective LyMa trial, a Lysa study. Paper presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.146.146"},{"key":"2016123117301575000_109.1.djw263.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"2016123117301575000_109.1.djw263.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"2016123117301575000_109.1.djw263.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23537"},{"key":"2016123117301575000_109.1.djw263.28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.575489"},{"issue":"2","key":"2016123117301575000_109.1.djw263.29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601","volume":"172","author":"Till","year":"2016","journal-title":"Br J Haematol."},{"key":"2016123117301575000_109.1.djw263.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"2016123117301575000_109.1.djw263.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"2016123117301575000_109.1.djw263.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08820.x"},{"key":"2016123117301575000_109.1.djw263.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"2016123117301575000_109.1.djw263.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"2016123117301575000_109.1.djw263.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"2016123117301575000_109.1.djw263.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"2016123117301575000_109.1.djw263.37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv364"},{"key":"2016123117301575000_109.1.djw263.38","doi-asserted-by":"crossref","unstructured":"Kaplan LD, Jung SH Stock W . Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403. Paper presented at the 57th meeting of the American Society for Hematology December 2015; Orlando, FL.","DOI":"10.1182\/blood.V126.23.337.337"},{"key":"2016123117301575000_109.1.djw263.39","doi-asserted-by":"crossref","unstructured":"Doorduijn JK Minnema MC Kersten MJ . Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study. Paper presented at the 57th meeting of the American Society for Hematology; December 2015; Orlando, FL.","DOI":"10.1182\/blood.V126.23.339.339"},{"key":"2016123117301575000_109.1.djw263.40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"2016123117301575000_109.1.djw263.41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050203"},{"key":"2016123117301575000_109.1.djw263.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2444"},{"key":"2016123117301575000_109.1.djw263.43","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.938333"},{"key":"2016123117301575000_109.1.djw263.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"2016123117301575000_109.1.djw263.45","doi-asserted-by":"crossref","unstructured":"Dreyling M Morschhauser F Bron D . Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed\/refractory, indolent or aggressive lymphoma. Paper presented at the 55th meeting of the American Society for Hematology; December 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.87.87"},{"key":"2016123117301575000_109.1.djw263.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"2016123117301575000_109.1.djw263.47","doi-asserted-by":"crossref","unstructured":"Wang ML Goy A Martin P . Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. Blood. Paper presented at the 56th annual meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.4471.4471"},{"key":"2016123117301575000_109.1.djw263.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"2016123117301575000_109.1.djw263.49","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12780"},{"key":"2016123117301575000_109.1.djw263.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"2016123117301575000_109.1.djw263.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"2016123117301575000_109.1.djw263.52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm463"},{"key":"2016123117301575000_109.1.djw263.53","doi-asserted-by":"crossref","unstructured":"Kuruvilla J. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed\/refractory non Hodgkin\u2019s lymphoma (NHL). Paper presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.396.396"},{"key":"2016123117301575000_109.1.djw263.54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"issue":"4","key":"2016123117301575000_109.1.djw263.55","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1038\/bcj.2014.71","article-title":"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed\/refractory lymphoma","volume":"17","author":"Assouline","year":"2014","journal-title":"Blood Cancer J."},{"key":"2016123117301575000_109.1.djw263.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"2016123117301575000_109.1.djw263.57","doi-asserted-by":"crossref","unstructured":"Davids MS Seymour JF Gerecitano JF . Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Paper presented at the meeting of the American Society for Clinical Oncology; June 2014; Chicago, IL.","DOI":"10.1200\/jco.2014.32.15_suppl.8522"},{"key":"2016123117301575000_109.1.djw263.58","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902856808"},{"key":"2016123117301575000_109.1.djw263.59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8793"},{"issue":"9","key":"2016123117301575000_109.1.djw263.60","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol."},{"key":"2016123117301575000_109.1.djw263.61","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12819"},{"key":"2016123117301575000_109.1.djw263.62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"key":"2016123117301575000_109.1.djw263.63","doi-asserted-by":"crossref","unstructured":"Morschhauser F Bouabdallah K Stilgenbauer S . Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma. Paper presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.3067.3067"},{"issue":"7","key":"2016123117301575000_109.1.djw263.64","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clml.2015.02.021","article-title":"A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"15","author":"Cassaday","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2016123117301575000_109.1.djw263.65","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.09.057"},{"key":"2016123117301575000_109.1.djw263.66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"2016123117301575000_109.1.djw263.67","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"2016123117301575000_109.1.djw263.68","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"issue":"1","key":"2016123117301575000_109.1.djw263.69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nature Med."},{"key":"2016123117301575000_109.1.djw263.70","doi-asserted-by":"crossref","unstructured":"Balasubramanian S Schaffer M Deraedt W, . Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Paper presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.78.78"},{"key":"2016123117301575000_109.1.djw263.71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541953"},{"issue":"2","key":"2016123117301575000_109.1.djw263.72","first-page":"2152","article-title":"Hematopoietic cell transplantation for mantle cell lymphoma: Predictive value of pre-transplant positron emission tomography\/computed tomography and bone marrow evaluations for outcomes","volume":"14","author":"Magnusson","year":"2014","journal-title":"Clin Lymph Myeloma Leuk."},{"key":"2016123117301575000_109.1.djw263.73","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.46"},{"key":"2016123117301575000_109.1.djw263.74","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802216707"},{"key":"2016123117301575000_109.1.djw263.75","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26731"},{"key":"2016123117301575000_109.1.djw263.76","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1469-2"},{"issue":"11","key":"2016123117301575000_109.1.djw263.77","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","article-title":"Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma?","volume":"55","author":"Kedmi","year":"2014","journal-title":"Leuk Lymp."},{"issue":"2","key":"2016123117301575000_109.1.djw263.78","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood."},{"issue":"10","key":"2016123117301575000_109.1.djw263.79","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood."},{"key":"2016123117301575000_109.1.djw263.80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"issue":"21","key":"2016123117301575000_109.1.djw263.81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.V124.21.147.147","article-title":"MRD eradication should be the therapeutic goal in mantle cell lymphoma and may enable tailored treatment approaches: Results of the intergroup trials of the European MCL Network","volume":"124","author":"Pott","year":"2014","journal-title":"Blood"},{"key":"2016123117301575000_109.1.djw263.82","doi-asserted-by":"crossref","unstructured":"Callanan MB Delfau MH Macintyre E , . Predictive power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; interim results from the LyMa-MRD Project, conducted on behalf of the Lysa Group. Paper presented at the 57th meeting of the American Society for Hematology; December 2015; Orlando, FL.","DOI":"10.1182\/blood.V126.23.338.338"},{"key":"2016123117301575000_109.1.djw263.83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3116"},{"key":"2016123117301575000_109.1.djw263.84","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11267"},{"issue":"6","key":"2016123117301575000_109.1.djw263.85","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leuk."},{"issue":"1","key":"2016123117301575000_109.1.djw263.86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.13182","article-title":"The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma","volume":"169","author":"Kalinova","year":"2015","journal-title":"Br J Haematol."},{"issue":"4","key":"2016123117301575000_109.1.djw263.87","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12409","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"162","author":"von Hohenstaufen","year":"2013","journal-title":"Br. J Haematol"},{"key":"2016123117301575000_109.1.djw263.88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"2016123117301575000_109.1.djw263.89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"2016123117301575000_109.1.djw263.90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0836"},{"key":"2016123117301575000_109.1.djw263.91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"2016123117301575000_109.1.djw263.92","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"issue":"23","key":"2016123117301575000_109.1.djw263.93","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Martinez","year":"2003","journal-title":"Cancer Res"},{"key":"2016123117301575000_109.1.djw263.94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0410"},{"key":"2016123117301575000_109.1.djw263.95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536433"},{"key":"2016123117301575000_109.1.djw263.96","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12854"}],"container-title":["Journal of the National Cancer Institute"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T16:10:02Z","timestamp":1601136602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djw263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,31]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,31]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1093\/jnci\/djw263"],"URL":"https:\/\/doi.org\/10.1093\/jnci\/djw263","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,31]]}}}